Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio

April 28, 2010

LELYSTAD and ‘S-HERTOGENBOSCH, The Netherlands, April 28, 2010
/PRNewswire/ — Pepscan, the Netherlands based biotechnology firm focusing on
protein mimicking technology for the generation of immune therapeutics, today
announced that it reached a partnering agreement for its therapeutic vaccine
portfolio with Immunovo BV of ‘s-Hertogenbosch. Under the terms of the
agreement Pepscan will receive an undisclosed cash payment as well as a
minority interest in Immunovo.

“Pepscan has recently refocused its R&D program on the application of its
proprietary CLIPSTM protein mimicry technology for the generation of
monoclonal antibodies and therapeutic peptides”, said Wim Mol, CEO of
Pepscan. “The agreement with Immunovo allows Pepscan to fully concentrate its
resources on a focused execution of its research program. We consider
Immunovo as an ideal partner to enhance the value of the therapeutic vaccine
portfolio we have developed over the years.”

“We are very pleased with the partnership with Pepscan on the therapeutic
vaccine portfolio” said Joost van Bree, CEO of Immunovo. “Pepscan created a
rich development pipeline of therapeutic vaccines, of which the most advanced
product is in Phase II clinical development. We are confident that with our
specific expertise we will be able to expedite the development of this
portfolio, which also includes a proprietary anti-VEGF-A vaccine that could
be useful for the treatment of certain cancers.”

Notes for the editor:

About Pepscan

Pepscan Holding NV is a privately owned company based in Lelystad, the
. The company focuses on protein mimicking technology for the
generation of therapeutic peptides and antibodies. It has developed a
pipeline of therapeutic vaccine and antibody programs, of which the most
advanced is in Phase II clinical testing. Pepscans proprietary CLIPSTM
technology has been proven to yield functional antibodies reactive with a
range of complex proteins, including GPCRs. For more information visit

About CLIPSTM technology

CLIPSTM (Chemical LInkage of Peptides onto Scaffolds) is a technology to
present one or more peptides in a structurally constrained configuration.
These molecules behave as functional mimics of complex protein domains and
hitherto have been used in antibody and vaccine programs to create superior
immunogens in the induction and selection of antibodies against disease
relevant protein targets. This is especially valuable in the case of proteins
that are inaccessible as recombinant proteins (e.g. GPCRs, ion channels,
patented proteins).

About Immunovo

Immunovo BV is a privately owned company, based in ‘s-Hertogenbosch, The
. The company focuses on immune-mediated inhibition of
extracellular signal transduction. Apart from a pipeline of
immunotherapeutics, Immunovo has developed proprietary immunostimulatory
technology that is unique in combining a high efficacy with a favourable
safety profile. For more information visit http://www.immunovo.com.

SOURCE Pepscan Holding N.V.

Source: newswire

comments powered by Disqus